KMC Speciality: standalone PAT up 49.6% YoY to ₹16.2 Cr on margin gains, QoQ growth cools
PAT +49.64% YoY · revenue +24.08% · margins expanding
₹92.94 Cr
+24.08% YoY
₹16.22 Cr
+49.64% YoY
17.18%
+2.9pp YoY
₹0.99
KMC Speciality Hospitals' standalone Q2 FY27 (quarter ended September 30, 2026) print is the test our pre-result preview flagged: whether the company could hold Q1's exceptional pace into a seasonally softer quarter. Revenue from operations came in at ₹92.94 Cr, up 24.1% YoY from ₹74.90 Cr, but only 1.3% above Q1 FY27's ₹91.78 Cr — effectively flat sequentially. Standalone PAT rose 49.6% YoY to ₹16.22 Cr (from ₹10.84 Cr) but slipped 2.1% QoQ from ₹16.57 Cr. That confirms the sequential cooling the preview was watching for, rather than a repeat of Q1's 120% YoY PAT surge.
Q2 FY-2027 vs prior quarters
The YoY margin expansion is real: net profit margin (PAT/total income) widened to 17.19% from 14.24% a year ago, and the EBITDA-level operating margin improved to roughly 30.5% from ~27.8%, as employee costs and other overheads grew slower than revenue while finance costs (₹1.93 Cr) and depreciation (₹6.19 Cr) stayed broadly flat YoY. Against Q1 FY27, though, NPM (17.71%) and OPM (~31.0%) were both marginally higher, so the quarter gave back a sliver of the margin gain rather than extending it. No exceptional items are disclosed in the statement or notes, so the 49.6% YoY PAT growth is also the clean, adjusted figure.
The stock went into the print at ₹171.9, up 5.8% over the past month of trading.
For context: revenue is at a 6-quarter high.
What the summary numbers don't show
EPS (basic, not annualised) ₹0.99 vs ₹0.66 YoY and ₹1.02 in Q1 FY27
Tax expense ₹5.42 Cr on PBT of ₹21.64 Cr (effective rate ~25%), up 46.8% YoY
Against our preview's expected ₹95–100 Cr revenue band, the ₹92.94 Cr print lands just below range, while the 17.19% NPM sits inside the flagged 16–18% band. The filing discloses neither occupancy nor ARPOB, so those two preview watch items — 84–88% occupancy and ₹32,500–33,500 ARPOB — remain unresolved this quarter. There is no formal sell-side consensus tracking KMCSHIL (confirmed via search), so vsStreet is unknown, and management has issued no prior guidance or outlook on record either; no management press release accompanies this filing beyond the board-meeting outcome letter, so there is no additional management commentary to reconcile against the numbers. The quarter's other filings — a 5.37% promoter share encumbrance and SEBI takeover-code disclosures (Sep 15, Oct 14), plus a trading-window closure (Sep 29) ahead of results — are procedural and carry no direct read on the operating numbers. Capital work-in-progress rose to ₹23.40 Cr from ₹12.34 Cr at FY26-end, consistent with the ₹519 Cr expansion plan referenced in the preview, while cash and equivalents closed the half at ₹82.62 Cr.
W1
Whether Q3 FY27 revenue breaks above the ₹92.94 Cr base after two quarters of near-flat sequential growth
W2
Occupancy and ARPOB disclosure — not reported this quarter; preview's 84-88% occupancy and ₹32,500-33,500 ARPOB bands remain unverified
W3
Margin trajectory — NPM/OPM both ticked down QoQ (17.19% vs 17.71%; ~30.5% vs ~31.0%) after YoY expansion; watch if this reverses or persists
Margin hold and occupancy trajectory the test after Q1's 120% PAT surge
KMC Speciality posted exceptional Q1 FY27 growth with PAT nearly doubling YoY. Q2 is the real proving ground: can the company sustain revenue momentum in a seasonally softer quarter, hold margin gains, and keep 86% occupancy on track amid a ₹519 Cr expansion push?
The setup: a momentum quarter meets seasonality
KMC Speciality Hospitals closed Q1 FY27 with exceptional momentum: revenue of ₹91.78 Cr (up 37.9% YoY, +11.6% QoQ) and standalone PAT nearly doubling YoY to ₹16.57 Cr. Occupancy surged to 86% from 69% a year prior. This was the company's strongest quarter in terms of absolute PAT and margin expansion. The Street, though thinly covered, has taken note — the stock trades at ₹177.5 (as of Nov 12), +156.87% off the 52-week low, and near ATH of ₹185.5. The question for Q2: does the momentum hold, or does seasonal softness (Q2 FY26 saw weaker case mix vs prior years) temper the print?
~₹95–₹100 Cr
On-plan extrapolation from Q1 at ~32% YoY growth; Q2 FY26 base was ₹76.1 Cr
~16–18%
Target: hold Q1 FY27's 17.7% margin as occupancy stabilizes. Weak outcome <15%
~84–88%
Q1 FY27 reached 86%; steady-state is on-plan. Fall below 80% signals patient flow slippage
₹32,500–₹33,500
Tracking the pricing power from Q1–Q2 FY26 trend (~₹32,710 in Q2 FY26). Watch for mix shift
A strong Q2 would show revenue crossing ₹100 Cr with margin holding 16%+, and occupancy stable or higher. Bed utilization is now a primary metric; any dip in case volume (especially elective surgeries, which often soften in summer months in India) or ARPOB compression would pressure PAT. A weak quarter would see revenue miss ₹95 Cr, margin compress to 14–15% (reflecting either cost inflation or pricing pressure), or occupancy fall below 82%—signs that the Q1 momentum was Q1-specific and not a reset.
Guidance and trajectory: the capex overhang
On August 14, the board approved ₹519 Cr in expansion capex for Trichy and Bengaluru campuses, including a four-floor extension to Trichy's Mother & Child Care Hospital. This is a material deployment of capital and signals management confidence in growth. However, the build-out will weigh on cash flow and ROI for 12–24 months. Full-year FY27 guidance has not been formally laid out in our records, so the question is: does management reiterate the trajectory (margin hold or further expansion, capex phasing), or is Q2 a call to recalibrate expectations on cash and returns?
What the Street says (thin coverage caveat)
Since last quarter: the filings scan
1 · Promoter encumbrance (Sep 15, 2026)
Sri Kauvery Medical Care (India) Limited, a promoter holding 75%, disclosed creation of encumbrances over 27.41 lakh shares (5.37% of issued). This is in addition to prior pledges. The quantum is material and worth monitoring for covenant pressure or capital access constraints at the promoter level.
2 · SEBI takeover disclosures (Sep 15, Oct 14, 2026)
Revised disclosures were filed under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations following BSE-flagged discrepancies. Status: routine compliance matter, resolved. No acquisition or threat announced.
3 · Trading window closure (Sep 29, 2026)
Window closed for designated persons ahead of Q2 result. Routine. Signals no leakage of surprise outcome ahead of Nov 13 board meet.
4 · Capex approval and cost auditor (Aug 14, 2026)
Board approved ₹519 Cr expansion across Trichy and Bengaluru. This is the headline capital deployment for FY27 and reflects confidence in medium-term growth, but will compress near-term free cash flow.
5 · Q1 FY27 result (Aug 14, 2026)
Revenue ₹91.78 Cr (+37.9% YoY), PAT ₹16.57 Cr (+120% YoY). The print was strong and justified the recent rally. Q2 is now measured against this high bar.
On result day: the checklist
1 · Revenue and margin trajectory
Look for ₹95+ Cr revenue and PAT margin ≥16%. Below ₹92 Cr or margin <14% is a miss and suggests Q1 was a peak, not a reset.
2 · Occupancy and case volume
Management will likely guide on bed days, patient mix, and ARPOB. Watch for any Q2 seasonality commentary—is summer elective slowdown priced in the numbers?
3 · Capex phasing and cash generation
With ₹519 Cr approved, the company should update capex run-rate, expected funding source (internal/debt), and impact on dividend/shareholder payouts.
4 · FY27 guidance reaffirmation
Listen for any management commentary on full-year revenue and margin expectations. Silence or a cut vs. implied trajectory would be a material signal.
KMC Speciality Hospitals delivered a breakout Q1 FY27 with +38% revenue growth and 120% PAT surge. Q2 is the critical follow-through: can the company sustain occupancy above 85%, hold margins near 17%, and post ₹95+ Cr revenue despite seasonal headwinds? The ₹519 Cr capex plan is a vote of confidence but raises the bar for cash-backed returns. With thin Street coverage, the result and management's tone will drive the next move, not consensus revisions. Watch occupancy trends, ARPOB stability, and any guidance update closely.